Aldn-084 [upd]

Unveiling ALDN-084: The Next Frontier in Therapeutic Innovation

As with any mysterious code, several theories have emerged to explain the significance of ALDN-084. Some speculate that it may be related to:

Initial speculations surrounding ALDN-084 suggest that it may be related to a novel compound, material, or technology. Some researchers have posited that ALDN-084 could be a code name for a new pharmaceutical or therapeutic agent. Others believe it might be connected to an emerging field of research, such as advanced materials science or nanotechnology. ALDN-084

Binding site:

A novel allosteric pocket located adjacent to the activation loop (Ser177/181) of IKKβ. X‑ray co‑crystallography (PDB 8XYZ) shows ALDN‑084 forming hydrogen bonds with Asp199 and a π‑π stacking interaction with Tyr199, stabilizing the “inactive” conformation of the kinase. Others believe it might be connected to an

3.1 Primary Target – IKKβ Allosteric Inhibition

“Someone… sent us a map,” Mei whispered. “A map to…?” ALDN-084

IUPAC name

| Property | Reported Value / Comment | |----------|--------------------------| | | Not disclosed (proprietary) | | Molecular formula | C₂₁H₂₅N₅O₂ (estimated from patent) | | Molecular weight | ≈ 383 Da | | Core scaffold | 1,3,5‑triazine linked to a heterocyclic quinazolinone via a sulfonamide bridge | | LogP (XLogP3-AA) | 2.8 – 3.2 (moderately lipophilic) | | pKa | 6.4 (basic amine), 9.8 (sulfonamide NH) | | Solubility | ~10 µM in PBS (pH 7.4); > 100 µM in 10 % DMSO/PBS | | Stability | Chemically stable at 25 °C for ≥ 12 months (solid form) | | Formulation | Currently supplied as a free‑base powder; developing an oral tablet (≤ 200 mg) and an IV solution (5 mg · mL⁻¹) |

While exact mechanisms can vary by compound, ALDN-084 is described in developer communications as acting on neurotransmitter systems and synaptic signaling involved in mood and emotional regulation. Investigational antidepressants often aim to:

Unraveling the Mystery